Tribenzor 12.5 mg/1 (Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide TABLET, FILM COATED) 12.5 mg/1

Tribenzor 12.5 mg/1 combines olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide for blood pressure management. This triple-action tablet is designed to support cardiovascular health.

Strength

12.5 mg/1

Pack Size

30 TABLET, FILM COATED in 1 BOTTLE (0713-0874-30)

Manufacturer / TM Owner

Cosette Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Tribenzor 12.5 mg/1 is commonly used for managing high blood pressure. It combines three active ingredients to help regulate blood pressure levels. This medication is often prescribed for individuals who require a multi-faceted approach to blood pressure control.

Side Effects

Common effects of Tribenzor 12.5 mg/1 may include dizziness, fatigue, and swelling in the legs or ankles. Some users may also experience headaches or nausea. These effects vary and are not experienced by everyone.

Precautions & Warnings

Tribenzor 12.5 mg/1 should be handled with care, especially for those with kidney or liver issues. It is important to follow the advice of a healthcare provider regarding its use. Regular monitoring of blood pressure is recommended.

Avoid Interactions

Tribenzor 12.5 mg/1 may interact with certain medications, including other blood pressure drugs, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs). Alcohol consumption should be moderated while using this medication.

Frequently Asked Questions

Tribenzor 12.5 mg/1 is used to manage high blood pressure by combining three active ingredients to support cardiovascular health.

Tribenzor 12.5 mg/1 is taken orally, typically once daily. Follow the instructions provided by your healthcare provider.

Common side effects may include dizziness, fatigue, and swelling in the legs or ankles. Always consult a healthcare provider for personalized advice.

Tribenzor 12.5 mg/1 may interact with other blood pressure drugs, diuretics, and NSAIDs. Always inform your healthcare provider about all medications you are taking.

Tribenzor 12.5 mg/1 may not be suitable for individuals with certain medical conditions, such as kidney or liver issues. Consult a healthcare provider for personalized advice.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.